AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06201884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early rehabilitation through Adapted Physical Activity
Description: From the day after surgery, 1 to 2 walking sessions with walking platform, lasting 6 to 30 minutes (min-max), will be proposed daily until the day of discharge.
Study NCT06333067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sofwave
Description: The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
Study NCT05916495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hybrid care arm
Description: Patients will be evaluated at 3 months via a remote review. This will review the patients-recorded spirometry and a questionnaire developed for this study which asses the patients' symptom burden and medication adherence. All patients participating in the study will be offered remote monitoring (patient facing app+ patient recorded home spirometry).
Study NCT05916495 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care arm
Description: Patients will be reviewed in clinic at 3 months per the standard of care. All patients participating in the study will be offered remote monitoring (patient facing app+ patient recorded home spirometry).
Study NCT05741840 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PBT-A
Description: PBT-A provides all the elements of family based treatment for children with obesity, including nutrition and physical activity education, behavior therapy skills, and parenting skills.
Study NCT05741840 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education (HE)
Description: The HE arm will provide information about nutrition, physical activity, sedentary behavior, sleep, emotions, and stress.
Study NCT03261375 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Artery Radiofrequency Ablation System (Generator and Catheter )
Description: A renal denervation system with a mesh 6-electrode radiofrequency ablation catheter and multi-channel radiofrequency generator
Study NCT03261375 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Antihypertensive Agents
Description: Calcium channel blocker, Diuretic
Study NCT03261375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihypertensive Agents
Description: Calcium channel blocker, Diuretic
Study NCT03261375 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: Catheterization without renal denervation
Study NCT05274165 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lyric Hearing Aid- Experimental Design
Description: Extended wear hearing aid with a fitting modification that is currently not available
Study NCT05274165 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lyric Hearing Aid- Commercially Available
Description: Extended wear hearing aid that is currently available
Study NCT05274165 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lyric Hearing Aid- Commercially Available
Description: Extended wear hearing aid that is currently available
Study NCT06215339 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet therapy training
Description: diet education
Study NCT06241456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT825
Description: FT825 will be administered as an intravenous (IV) infusion at planned dose levels.
Study NCT06260098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga with High Breath work & meditation; Low movement/postures
Description: Participants will engage in an 8 week asynchronous yoga class focused on the internal and cognitive experience within the practice using breathing and meditation focused techniques.
Study NCT06260098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga with Low Breath work & meditation; High movement/postures
Description: Participants will engage in an 8 week asynchronous yoga class with a emphasis on the physicality and movements of the practice.
Study NCT04916769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib capsule
Description: 500 mg dose of bosutinib capsule contents mixed with applesauce
Study NCT04916769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib capsule
Description: 500 mg dose of bosutinib capsule contents mixed with yogurt
Study NCT04916769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bosutinib capsule
Description: 500 mg dose of intact bosutinib capsules
Study NCT05879835 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KiteLock 4% Sterile Catheter Lock Solution
Description: KiteLock™ is a clear, colorless, and sterile 4% (40 mg/ml) tetrasodium EDTA solution that contains no preservatives, latex, antibiotics, or ethanol and is nonpyrogenic. Tetrasodium salt of EDTA has been shown to disrupt in vivo and ex vivo-generated biofilms by destabilizing the structural integrity of micro-organisms at the cellular level.
Study NCT05879835 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heparin Lock Solution
Description: Nonpyrogenic, hypertonic preparation of heparin sodium injection, USP with sodium chloride in water for injection.
Study NCT06241456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered as an IV infusion at planned dose levels.
Study NCT06241456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered as an IV infusion at planned dose levels.
Study NCT05417217 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Discontinued ventilation
Description: Ventilation is discontinued after going on CPB and lungs are exposed to atmospheric pressure
Study NCT05417217 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continued ventilation
Description: Ventilation is continued from going on CPB until clamping of the ascending aorta with tidal volume 3ml/kg ideal body weight, Fraction of inspired oxygen (FiO2) 50%, respiratory rate 5/min and Inspiratory:Expiratory (I/E) ratio 1/2.
Study NCT05736198 — intervention group
Intervention type: DRUG
Intervention: Dexmedetomidine
Description: dexmedetomidine, midazolam, and fentanyl (titrated to effect) to facilitate intubation
Study NCT05633693 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Counterpressure Maneuvers
Description: Movements that can aid in delaying or preventing syncope by recruiting skeletal muscle pumping (via compression of major veins by contracting muscle to eject blood through cardiovascular circuit) and increased sympathetic drive (via sustaining an isometric muscle contraction). In this trial, we will be evaluating two clinically recommended isometric maneuvers (crouching, and leg crossing with muscle tensing) and two novel dynamic maneuvers that comprise discrete movement that the investigators have identified in prior work (exaggerated anterior-posterior postural sway, rhythmic gluteal clenching).
Study NCT05633693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counterpressure Maneuvers
Description: Movements that can aid in delaying or preventing syncope by recruiting skeletal muscle pumping (via compression of major veins by contracting muscle to eject blood through cardiovascular circuit) and increased sympathetic drive (via sustaining an isometric muscle contraction). In this trial, we will be evaluating two clinically recommended isometric maneuvers (crouching, and leg crossing with muscle tensing) and two novel dynamic maneuvers that comprise discrete movement that the investigators have identified in prior work (exaggerated anterior-posterior postural sway, rhythmic gluteal clenching).
Study NCT05633693 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Baseline Stand
Description: Participants will stand quietly for 5-minutes on a force platform to allow the investigators to assess their typical response to orthostasis.
Study NCT05633693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline Stand
Description: Participants will stand quietly for 5-minutes on a force platform to allow the investigators to assess their typical response to orthostasis.
Study NCT06299839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAS-004 Capsules
Description: A mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MAPK/ERK kinase, or MEK) 1/2 inhibitor presented in 1 mg, 4mg, and 10 mg strength capsules, intended for oral administration once daily.
Study NCT06299839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAS-004 Tablets
Description: A mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MAPK/ERK kinase, or MEK) 1/2 inhibitor presented in 4mg strength tablets, intended for oral administration once daily.
Study NCT06051591 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food FARMacia Program
Description: Twice monthly delivery of groceries with about 12 meals per household member for up to 4 household members for 6 months.
Study NCT06051591 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-directed meal preparation support
Description: Nutrition education and anticipatory guidance to support healthy meal preparation
Study NCT06051591 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-directed meal preparation support
Description: Nutrition education and anticipatory guidance to support healthy meal preparation
Study NCT06330051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: improvement acute reperfusion treatment quality for stroke through spatiotemporal computing
Description: 1. Intelligent bracelet automatic positioning device and data feedback system based on spatiotemporal computing technology~2. Continuous in-hospital procedure improvement based on P-D-C-A cycle for AIS
Study NCT06490731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Patients will receive dexmedetomidine
Study NCT06490731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: patients Will receive ketamine
Study NCT04305678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab (Nucala) 400 mg SC every 4 weeks x 24 weeks
Study NCT06648798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Limber Limb
Description: Participants will be involved for two months using a non-inferiority design in which the participant will be assessed using their normal device (1 month) and the study device (1 month).
Study NCT05270213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBS2418
Description: RBS2418 is a potent and selective small molecule inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1). RBS2418 as monotherapy potentially can have an activating effect on the anti-tumor innate immune response and lead to anti-tumor responses in adult subjects with advanced or metastatic tumors.
Study NCT04886284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem
Description: Adjunctive ertapenem
Study NCT04886284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline placebo
Study NCT05959486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR6002A
Description: One tablet administered alone
Study NCT05959486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR6002B
Description: One tablet administered alone
Study NCT05959486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR6002
Description: One capsule administered alone
Study NCT05454085 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Bisphenol-A
Description: measurement of BPA levels in maternal blood and amniotic fluid
Study NCT02831335 — intervention group
Intervention type: OTHER
Intervention: MRI
Description: Perform MRI studies
Study NCT02831335 — intervention group
Intervention type: OTHER
Intervention: Group 4
Description: Perform MRI studies
Study NCT05833139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1810631
Description: BI 1810631
Study NCT05833139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole
Study NCT04845685 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor (CGM)
Description: A device that measures blood sugar levels every 1-5 minutes
Study NCT05130281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maya mobile app
Description: The Maya app teaches cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, and exposure to help individuals with anxiety.
Study NCT05130281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support
Description: Participants earn points and badges for completing sessions, homework, and skills on time and receive post session feedback via text message. Participants can identify a person they know to receive updates about their progress and support them throughout their time in the program. Participants will not be required to choose a person they know to receive updates about their use of the program; instead, they can choose to have a member of the study team serve as their social support if they are assigned to this condition.
Study NCT05130281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gain Framed
Description: Participants earn points and badges for completing sessions, homework, and skills on time and receive post session feedback via text message.
Study NCT05130281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss Framed
Description: Participants lost points and badges for not completing sessions, homework, and skills on time and receive post session feedback via text message.
Study NCT06311734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LW231 tablets
Description: P.O.
Study NCT06311734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: P.O.
Study NCT05868044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRIMUS
Description: PRIMUS system
Study NCT05725668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dual-task tai ji quan
Description: dual-task tai ji quan training
Study NCT05725668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard tai ji quan
Description: standard tai ji quan training
Study NCT05725668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stretching
Description: stretching exercise
Study NCT04932512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION224
Description: ION224 will be administered by SC injection.
Study NCT04932512 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ION224-matching placebo solution will be administered by SC injection.
Study NCT05273996 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sertraline, bupropion, desvenlafaxine
Description: Study geriatric psychiatrists prescribe FDA-approved antidepressants using a treatment algorithm consistent with the STAGED (Duke Somatic Treatment Algorithm for Geriatric Depression) approach, with standardization of treatment in the first six months beginning with sertraline, with the option of augmentation with bupropion or switch to desvenlafaxine. Beyond six months of acute treatment, subjects are treated based on the study psychiatrist's clinical assessment and recommendations, consistent with STAGED guidelines.
Study NCT06509334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JYB1904
Description: Participants will receive JYB1904 at week0 and receive placebo at week4,8,12
Study NCT06509334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JYB1904
Description: Participants will receive JYB1904 at week0,8 and receive placebo at week4,12
Study NCT06509334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Participants will receive Omalizumab every 4 weeks for 12 weeks
Study NCT05455385 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard 12-week rehabilitation program
Description: The standard program consisted of 1 session in the fitness room and 1 session in the sports hall/week during 12 weeks.
Study NCT05455385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard 12-week rehabilitation program
Description: The standard program consisted of 1 session in the fitness room and 1 session in the sports hall/week during 12 weeks.
Study NCT05455385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: extra session hydrotherapy
Description: The hydrotherapy group receives 1.5h additional hydrotherapy/week in addition to the standard program.
Study NCT05455385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: extra session ground exercises
Description: The ground exercise group, receives 1.5h ground exercises/week in addition to the standard program.
Study NCT06529042 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study NCT05268055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sign Here training intervention
Description: Training film to educate healthcare providers to competently and sensitively interact with Deaf patients in healthcare settings.
Study NCT05268055 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intervention as usual
Description: Communicating with People Who Are Deaf or Hard of Hearing in Hospital Settings (https://archive.ada.gov/hospcombrprt.pdf)
Study NCT06660550 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic inguinal hernia repair
Description: traditional laparoscopic repair
Study NCT06660550 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Needlescopic inguinal hernia repair
Description: Needlescopic inguinal hernia repair
Study NCT05633797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FibriCheck
Description: During the patient's intensive care unit (ICU) stay, they will be monitored constantly to detect atrial fibrillation (standard care). After ICU dismissal, patients will be monitored using the FibriCheck application to detect atrial fibrillation until 30 days postoperative. Patients need to use the FibriCheck application for a minimum of 3x/day and can perform extra measurements when symptoms are present.
Study NCT06589830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL938 Capsules
Description: Oral administration
Study NCT06589830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Intravenous (IV) infusion
Study NCT05961059 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2.5 μg InvaplexAR-Detox
Description: 2.5 μg intramuscular dose of Sfl2a InvaplexAR-Detox.
Study NCT06508099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: 300 000 IU single dose orally
Study NCT05961059 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 μg InvaplexAR-Detox
Description: 10 μg intramuscular dose of Sfl2a InvaplexAR-Detox.
Study NCT06413069 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Raw whole almonds
Description: Subjects will be supplemented with 60 grams of almonds (treatment) or left untreated (no-nut group) for 16 weeks. Patients of the no-nut group will receive 6,7 kgs of almonds after finishing the study, supporting their compliance as untreated group.
Study NCT05961059 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.1 μg of dmLT
Description: 0.1 μg intramuscular dose of double mutant (LT R192G/L211A) enterotoxigenic Escherichia coli heat labile toxin (dmLT).
Study NCT05961059 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vaccination with commercially available saline solution.
Study NCT06468215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Option 1 is a single-drug regimen, with oral medroxyprogesterone acetate (MPA) 500mg/d or MA 320mg/d.
Description: Compare the efficacy of mono-therapy with progesterone versus combined therapy to determine the best treatment option.
Study NCT06508099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 100 000 IU single dose orally
Study NCT06042127 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: POEM-F
Description: POEM-F would be performed as described in the arms section
Study NCT06042127 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional POEM
Description: Anterior POEM performed as described in the arms section
Study NCT05670847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exogenous ketone ester
Description: 500 mg/kg orally three times daily (with at least 4 hours between each dose) for 28 days
Study NCT06517823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib + Cyanocobalamin fixed dose
Description: One tablet of 90 mg / 0.50 mg a day
Study NCT06517823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib fixed dose
Description: One pill of 90 mg a day
Study NCT06058078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RY_SW01 cell injection
Description: Injected RY_SW01 allogonic umbilical cord-derived mesenchymal stem cells(UCMSCs)
Study NCT06058078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basic treatment
Description: Drugs for LN treatment
Study NCT06058078 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Basic treatment
Description: Drugs for LN treatment